ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to with your ASCO member or guest account, and visit the subscription center available under your account profile.

Showing results for Affordable Care Act

May 9, 2017

On May 4, the U.S. House of Representatives passed H.R. 1628, the "American Health Care Act" (AHCA), in a 217-213 vote. The bill would repeal and at least partly replace the Affordable Care Act if signed into law. 

April 4, 2017

On Friday, March 24, the U.S. House of Representatives withdrew H.R. 1628, the "American Health Care Act" (AHCA), which would have repealed and partly replaced the Affordable Care Act (ACA). House Members were unable to come to an agreement on enough key details to pass the bill. 

April 3, 2017

A recent study, “Insurance denials for cancer clinical trial participation after the Affordable Care Act (ACA) mandate”, published in Cancer found that real or perceived lack of coverage of routine cost of cancer clinical trials persist following the passage of the ACA. The authors conclude that these persisting coverage denials and delays remain a substantial barrier to patient participation in cancer clinical trials.

March 7, 2017

On March 06, 2017, the United States House of Representatives released the American Healthcare Act, a bill to repeal and partly replace the Affordable Care Act (ACA). 

March 7, 2017

ASCO has submitted comments in response to the Affordable Care Act Market Stabilization proposed rule, published in the Federal Register on Feb. 17. The society has serious concerns that the proposal could reduce access to cancer care in significant ways.

February 21, 2017

On Feb. 15, 2017, ASCO leadership and members of the ASCO Government Relations Committee (GRC) met with key federal agency and congressional committee staff to discuss ASCO's top policy priorities. Discussions focused on federal efforts to repeal and replace the Affordable Care Act (ACA), implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) and the 21st Century Cures Act, among other matters.  

February 7, 2017

With the new Congress and Administration in place, ASCO has been on Capitol Hill monitoring the issues that affect the cancer care community, and educating lawmakers on how best to serve Americans with cancer. In particular, ASCO is closely tracking efforts to repeal and replace the Affordable Care Act (ACA), the discussion on the future of Medicaid, and relevant cabinet appointments.  

January 24, 2017

As the new Administration gets underway and Congress considers proposals to repeal and replace the Affordable Care Act, ASCO is closely monitoring developments and will continue to strongly urge policymakers to provide access to affordable and sufficient healthcare coverage for all Americans, as stated in the society’s principles for patient-centered healthcare reform.

January 11, 2017

ASCO has released, “ASCO Principles for Patient-Centered Healthcare Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. healthcare delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider the critical underpinnings of any healthcare reform proposal, the needs of patients facing a cancer diagnosis are met.

January 10, 2017

As the leading medical professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient care, ASCO is dedicated to working with policymakers and the entire cancer community to provide equal access to quality health care with special emphasis on reducing insurance and economic barriers to cancer care. 

January 9, 2017

On January 3rd, the 115th Session of the U.S. Congress got underway. One of the first orders of business was appointing new leadership of Committees, including those with jurisdiction over issues of importance to cancer-related policy.